liver transplant is the treatment of choice Nonsurgical treatments (PEI, RFA, and TACE) are employed to minimize drop-out from the transplant waiting list, which nevertheless occurs in 20% of ...

Hepatic resection and transplantation remain the standard curative therapies for hepatocellular carcinoma ... liver disease are best served by transplant evaluation; however, the best treatment ...

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...

I was approved for a transplant, and just two days later ... Two months later, I was diagnosed with hepatocellular carcinoma, a type of liver cancer that's common in people with liver failure.

This study investigated the long-term prognosis and clinical course of patients who survived for more than 5 years after hepatocellular carcinoma (HCC) diagnosis.This retrospective cohort study used ...

A newly developed nomogram predicts preoperative microvascular invasion in patients with HCC, improving surgical planning and outcomes.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the ...

Announcing a new publication for Acta Materia Medica journal. Icaritin (ICA) is a prenylflavonoid natural product extracted from plants of the Epimedium genus.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.